You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》匯豐研究:「可復美」產品負面新聞令巨子生物(02367.HK)增長可見度下降 目標價降至74.6元
阿思達克 07-23 11:27
匯豐研究發表研究報告指,巨子生物(02367.HK)在「618」促銷期間遭遇負面新聞影響,旗下品牌「可復美」的產品被指重組膠原蛋白含量遠低於產品標示,導致公司增長可見度降低,相應將其2025至2027年盈利預測下調6%,目標價從81.9元下調至74.6元。 匯豐研究指,巨子生物管理層仍維持2025年收入增長25%至28%及淨利潤增長21%至24%的目標,期望下半年銷售能彌補「618」期間的遜色表現。但該行認為負面影響是否能在下半年完全消除,尚待觀察,預計可復美品牌下半年的增長可能較現時的指引低10%,因此將2025年收入及淨利潤預測分別下調4.7%及6.1%,預計全年淨利潤將增長15.9%至23.91億元人民幣,較市場預期低4.5%。該行仍維持「買入」評級,認為巨子生物的增長潛力較國內同業優勝。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account